Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complement System01:27

Complement System

2.4K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
2.4K
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

548
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
548
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

475
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
475
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Disorders of the Nervous Tissue01:28

Disorders of the Nervous Tissue

1.3K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
1.3K
The Blood-brain Barrier00:49

The Blood-brain Barrier

47.3K
Overview
47.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Shifting From Systemic to Precision-Targeted Complement Therapies: Opportunities and Hurdles.

European journal of immunology·2026
Same author

Dysregulation of complement at the synapse in P301S mice and human tauopathies.

Acta neuropathologica communications·2026
Same author

Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravis.

Med (New York, N.Y.)·2026
Same author

Complement in brain and eye disease: shared mechanisms, convergent pathologies, and common therapeutic opportunities.

Mammalian genome : official journal of the International Mammalian Genome Society·2026
Same author

Activation of the Lectin Pathway Drives Persistent Complement Dysregulation in Long COVID.

Immunology·2026
Same author

<i>HLA's</i> hidden hand in Alzheimer's disease-five research questions en route to an answer.

Brain communications·2025
Same journal

Human cytomegalovirus at the maternal-fetal interface: an overview of pathogenesis, defence, and interventions.

Clinical science (London, England : 1979)·2026
Same journal

Cardiometabolic regulation by adipocyte-derived leptin and the brain melanocortin system.

Clinical science (London, England : 1979)·2026
Same journal

Impact of impaired branched-chain amino acid metabolism on kidney disease.

Clinical science (London, England : 1979)·2026
Same journal

Ex vivo pretreatment of donor organ with siRNA nanoparticles attenuates cold ischemia-reperfusion injury in cardiac transplantation.

Clinical science (London, England : 1979)·2026
Same journal

IL-22BP Attenuates Right Ventricular Remodeling in Pulmonary Arterial Hypertension.

Clinical science (London, England : 1979)·2026
Same journal

FGF2 in the regulation of regenerative repair and fibrosis: TGF-β cross-talk and therapeutic advances.

Clinical science (London, England : 1979)·2026
See all related articles

Related Experiment Video

Updated: Jun 30, 2025

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.8K

The complement system in neurodegenerative diseases.

Jacqui Nimmo1, Robert A J Byrne1, Nikoleta Daskoulidou1

  • 1UK Dementia Research Institute Cardiff, Cardiff University, Cardiff CF24 4HQ, U.K.

Clinical Science (London, England : 1979)
|March 20, 2024
PubMed
Summary
This summary is machine-generated.

The complement system drives inflammation in neurological diseases like Alzheimer's, Parkinson's, schizophrenia, and multiple sclerosis. Targeting complement may offer new therapies for these conditions.

Keywords:
complementdementiainflammation

More Related Videos

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures
10:05

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures

Published on: March 18, 2021

6.9K
A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
06:43

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes

Published on: February 5, 2018

12.2K

Related Experiment Videos

Last Updated: Jun 30, 2025

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.8K
A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures
10:05

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures

Published on: March 18, 2021

6.9K
A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
06:43

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes

Published on: February 5, 2018

12.2K

Area of Science:

  • Immunology
  • Neuroscience
  • Pathology

Background:

  • The complement system is vital for innate immunity and clearing immune complexes.
  • Proper regulation of complement-mediated inflammation is essential for its protective functions.
  • Dysregulated complement activation contributes to pathological inflammation in various diseases, including neurological disorders.

Purpose of the Study:

  • To review the evidence implicating the complement system in neurodegenerative diseases.
  • To focus on Alzheimer's disease, Parkinson's disease, schizophrenia, and multiple sclerosis.
  • To briefly discuss the therapeutic potential and challenges of anti-complement drugs.

Main Methods:

  • Literature review of studies investigating complement's role in neurological diseases.
  • Analysis of evidence linking complement activation to disease pathology.
  • Discussion of potential anti-complement drug therapies.

Main Results:

  • Growing evidence implicates the complement system in neuroinflammatory and neurodegenerative diseases.
  • Complement plays a role in Alzheimer's, Parkinson's, schizophrenia, and multiple sclerosis.
  • Neurodegeneration is a significant feature in these diverse neurological conditions.

Conclusions:

  • The complement system is a key driver of pathology in a range of neurological diseases.
  • Targeting the complement system presents potential therapeutic strategies for neurodegenerative diseases.
  • Further research is needed to fully understand the therapeutic potential and pitfalls of anti-complement therapies.